William Zaks, MD
Endocrinology, Diabetes & Metabolism · Grand Forks, NDNPI 1437249307
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $55,599 of the $63,161 with a category attached, or 88.0%. Novo Nordisk accounts for 94.4% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2021 at $19,584 and has fallen 97.7% since, to $445 in 2025.
Across 168 payments — averaging $375.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$60K
- Sanofi-aventis U.S. LLC$1K
- Merck$533
- AstraZeneca$439
- Boehringer Ingelheim$213
- Abbott$203
- plus $820 from 10 others
What the payments were for
- Speaking & faculty fees$55,59988%
- Travel & lodging$2,0293%
- Food & beverage$5,3408%
- Education$1940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $59,629 |
| Sanofi-aventis U.S. LLC | 39 | $1,324 |
| Merck | 7 | $533 |
| AstraZeneca | 9 | $439 |
| Boehringer Ingelheim | 5 | $213 |
| Abbott | 4 | $203 |
| Bayer | 4 | $169 |
| Lilly USA, LLC | 3 | $159 |
| Phathom Pharmaceuticals, Inc. | 1 | $98 |
| Amgen | 1 | $87 |
| Dexcom, Inc. | 3 | $86 |
| Johnson & Johnson | 1 | $64 |
| Novartis | 2 | $62 |
| Tandem Diabetes Care, Inc. | 2 | $45 |
| BETA Bionics, Inc. | 3 | $37 |
| Medtronic | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few endocrinology, diabetes & metabolism providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 387 | $429,170 |
| JardianceEmpagliflozin | 158 | $150,499 |
| FarxigaDapagliflozin Propanediol | 179 | $135,200 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 94 | $73,297 |
| Tresiba Flextouch U-200Insulin Degludec | 78 | $73,042 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 32 | $59,242 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 125 | $58,691 |
| Tresiba Flextouch U-100Insulin Degludec | 42 | $50,080 |
| ForteoTeriparatide | 11 | $49,418 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 258 | $49,224 |
| Humalog Kwikpen U-100Insulin Lispro | 140 | $47,415 |
| Novolog FlexpenInsulin Aspart | 140 | $45,704 |
| EliquisApixaban | 72 | $45,681 |
| JanuviaSitagliptin Phosphate | 23 | $41,779 |
| RybelsusSemaglutide | 31 | $39,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $59,629 | $468,504418 claims |
| Boehringer IngelheimJardiance | $213 | $150,499158 claims |
| AstraZenecaFarxiga, Symbicort | $439 | $138,353192 claims |
| Lilly USA, LLCForteo, Trulicity, Mounjaro, Humalog, Insulin Lispro | $159 | $118,14786 claims |
| MerckJanuvia | $533 | $41,77923 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,324 | $27,43029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology, diabetes & metabolism providers in North Dakotaon file to place this against a meaningful peer group, so we don't.
Other endocrinology, diabetes & metabolism in Grand Forks
- Bilal AhmedBismarck$7K
- Rodhan KhthirBismarck$2K
- Mario RiveraFargo$1K
- Raul Ruiz EspondaFargo$523
- Soamsiri NiwattisaiwongFargo$383
- David NewmanFargo$134
- Niyutchai ChaithongdiFargo$36
- William NewmanFargo$28
- Bharat RamanFargo$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.